Search for Current Clinical Trials

Study Name Description Trial Category Trial SubCategory
NRG BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Cancer Breast
NRG-GI002 A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer Cancer Gastro-Intestinal
NRG-GU002 Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel Cancer Prostate
NRG-GY005 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Cancer Gynecology - Ovarian, Fallopian Tube or Primary Peritoneal Cancer
OPUS A registry of patients taking Opsumit for pulmonary hypertension Heart & Vascular Hypertension
S0820 - Prevention of High-Risk Colorectal Polyps and New Colorectal Cancers PACES S0820 is a study to determine the efficacy of certain drugs in the prevention of high-risk colorectal polyps and new colorectal cancers in patients with previously treated colorectal cancer. Cancer Gastro-Intestinal
S1418/BR006 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Cancer Breast
S1507 A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies Cancer Lung
S1609 - DART DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors. Single arm nivolumab and ipilimumab treating patients with rare tumors Cancer Rare Tumor
TAPUR Study for Advanced Cancers The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. For more information please visit Cancer Genomic testing based trial